Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use.
Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.
Reihe
Auflage
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Technology
Zielgruppe
Für Beruf und Forschung
Researchers in genetics, molecular biology, oncology, pharmaceutical science, and clinical therapy who are interested in the role of epigenetics in cancer biology or those seeking novel means to treat cancer
Maße
Höhe: 235 mm
Breite: 191 mm
Gewicht
ISBN-13
978-0-323-91367-6 (9780323913676)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Steven Gray is a Senior Clinical Scientist and Adjunct Assistant Professor in the Thoracic Oncology Research Group, Trinity Centre for Health Sciences at St. James's Hospital, Dublin, Ireland.
Herausgeber*in
Senior Clinical Scientist and Adjunct Assistant Professor, Thoracic Oncology Research Group, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland
1. Introduction
Part 1: Introduction and Key Concepts
2. DNA Methylation and Hydroxymethylation in Cancer
3. Writers, Readers, and Erasers of Epigenetic Marks
4. Oncohistones
5. MicroRNAs, epi-miRNAs and Cancer
6. Long Noncoding RNAs and Cancer
7. The Epitranscriptome
8. Mining the Epigenetic Landscape: Surface Mining or Deep Underground - Alecsandar Milosavljevic
9: Epigenetics Clocks: Concepts for Carcinogenesis10: Environmental Pollution Epigenetics and Cancer
Part 2: Epigenetics and Cancer
11. Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality
12. Epigenetic Therapy in Lung Cancer
13. Breast Cancer Epigenetics
14. Therapeutic Applications of the Prostate Cancer Epigenome
15. Neuroblastoma
Part 3: Targeting Aberrant Epigenetics
16. Nutritional Epigenetic Regulators in the Field of Cancer: New Avenues for Chemopreventive Approaches -
17. Emerging Epigenetic Therapies- Lysine Methyltransferase/PRC Complex Inhibitors
18. Inhibitors of Jumonji C-Domain Histone Demethylases
19. Emerging Epigenetic Therapies: Lysine Acetyltransferase Inhibitors
20: Histone Deacetylases
21. Emerging Epigenetic Therapies
Part 4: Issues to Overcome/Areas of Concern
22. Genetic Intratumoral Heterogeneity
23. Challenges for single cell epigenetic analysis
24. Epigenetics Underpinning DNA Damage Repair
25. Epigenetics of Cisplatin Resistance
26. Therapeutically Targeting Epigenetic Regulation of Cancer Stem Cells
Part 5: Future Directions: Translation to the Clinic
27. Personalized Epigenetic Therapy-Chemosensitivity Testing
28. Personalized Therapy-Epigenetic Profiling as Predictors of Prognosis and Response
29. Epigenetic Priming - Fact or Fallacy
30. CRISPR and epigenetics
31. Epigenetics and CAR-T
